Epi CanaryEpi Canary
  • Home
  • Feed
  • Synthesis
  • Assessments
  • Scopes
  • Reliability
  • Sources
Epi Canary — Epidemic IntelligenceEvidence-led epidemic intelligence. Source-attributed evidence.
Arcede logoMade by Arcede
← Scopes/
Mpox (Clade I & II)Vector Borne
  • Overview
  • Synthesis
  • Assessments
  • Evidence

Public note

For situational awareness and research transparency. Not medical advice.

Vector Borneactive

Mpox (Clade I & II)

Tracking clade Ib geographic expansion, sustained human-to-human transmission chains, and antiviral resistance signals.

Open assessments

4

Tracked assessments currently open in this scope.

Evidence items

134

Source-attributed evidence available to this scope.

Source feeds

4

Configured sources contributing data to this investigation.

Last activity

Apr 12, 2026

Most recent scope activity captured in the system.

Evidence quality mix

T018
T145
T238
T324
T49

01

Synthesis

The current analyst view of this scope, at increasing levels of depth.

Elevated monitoring. Clade Ib geographic expansion is ongoing.

Mpox clade Ib has established sustained transmission in the DRC and neighboring countries. Cases have been reported in 4 new African countries since January 2026. WHO AFRO is coordinating ring vaccination with MVA-BN. The system is monitoring for antiviral resistance (tecovirimat), geographic expansion beyond East/Central Africa, and genomic evolution rate.

02

Assessments

Open assessments being tracked inside this scope, ordered for fast review.

Mpox clade Ib will be confirmed in at least 2 East African countries outside the DRC by April 2026.

Geographic Spread·resolved·85%·Through Apr 30, 2026·22 linked items·Mar 22, 2026

03

Recent evidence

The most recent source-attributed evidence flowing into this investigation.

WHO confirms 47 mpox clade Ib cases in Rwanda, marking the second East African country outside DRC with sustained transmission.

Mar 22, 2026
T1·WHO Disease Outbreak News·1 linked assessment
Auto-taggedOutbreakMutation